Skip to Content

Aquestive Therapeutics, Inc.

Securities Class Action

  • Date:
  • 1/20/2026
  • Company Name:
  • Aquestive Therapeutics, Inc.
  • Stock Symbol:
  • AQST
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ:AQST) on behalf of Aquestive stockholders. Our investigation concerns whether Aquestive has violated the federal securities laws and/or engaged in other unlawful business practices.

On January 9, 2026, Aquestive disclosed that it received a notice from the FDA that it “had identified deficiencies in the New Drug Application (NDA) submitted by the Company for its product candidate, Anaphylm™ (epinephrine) Sublingual Film, for the treatment of severe allergic reactions, including anaphylaxis, that preclude discussion of labeling and post-marketing commitments for Anaphylm.” Following this news, the price of the Company’s stock dropped.

If you purchased or otherwise acquired Aquestive shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.

Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions regarding the case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Aquestive Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: